Liv Pure Peptide Product: TIRZEP GLP-2

Liv Pure Peptides TIRZEP GLP-2 (TZP) Categories: Glp, Weight Loss $499.99 CAS# 2023788-19-2 Formula: C225H348N48O68 Molecular Weight: 4813.527 g/mol

Tirzepatide (Tirz) is a synthetic peptide analog engineered as a dual agonist of both the GIP and GLP-1 receptors. Designed for preclinical investigations, it has been shown to enhance glucose-stimulated insulin secretion, suppress glucagon release, delay gastric emptying, and reduce inflammatory markers. This multifunctional agent is under evaluation for its roles in metabolic regulation, adipose tissue remodeling, and tissue repair pathways.

For Research Use Only – Not for Human Consumption.

Sizes

10 mg

15 mg

20 mg

30 mg

View COA: 02092611

Liv Pure Peptides Products: TIRZEP GLP-2 60mg

At Liv Pure Peptides, innovation meets purity. Our advanced research and rigorous quality standards deliver breakthrough peptide solutions for better health and science.

Shop Products

Products

Pages

Legal

Newsletter Signup

YOU MUST BE OVER 21 YEARS OLD TO USE THIS WEBSITE.

All products provided by Liv Pure are intended solely for in‑vitro laboratory research purposes. These materials are expressly forbidden for any form of human or animal use, ingestion, or administration, and all products are sold strictly for research, laboratory, or analytical purposes – not for human consumption.

The products offered on this platform are not formulated, designed, or intended to diagnose, cure, mitigate, treat, or prevent any diseases or medical conditions. Additionally, these statements have not been evaluated by the Food and Drug Administration, and our products are not intended to diagnose, treat, cure, or prevent any disease.

All products are for Research and Development use only and are not for human consumption.

Liv Pure is a chemical supplier; LIV Pure Peptides is not a compounding pharmacy or chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act, nor is it an outsourcing facility as defined under Section 503B of the Act.